(1592–1611) Vasculitis – ANCA-Associated Poster II

Monday, October 27, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System
Abstract Poster Presenter: Naomi Patel, MD, MPH – Massachusetts General Hospital
10:30 AM - 12:30 PM Central Time

Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
Abstract Poster Presenter: Takashi Yamane, MD;PhD – Kakogawa Central City Hospital
10:30 AM - 12:30 PM Central Time

Antibiotic Prophylaxis During Treatment of Anca-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Abstract Poster Presenter: Natasha Le Blanc, MD, BSc – McGill University
10:30 AM - 12:30 PM Central Time

Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis
Abstract Poster Presenter: Irene Carrión-Barberà, MD, PhD – University of Washington
10:30 AM - 12:30 PM Central Time

Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
Abstract Poster Presenter: Caterina Ricordi, MD – AUSL-IRCCS of Reggio Emilia and University of Modena and Reggio Emilia
10:30 AM - 12:30 PM Central Time

A Multicenter Prospective Longitudinal Observational Study to Determine Safety of Extended Treatment with Rituximab in Maintaining Remission in Patients with ANCA Associated Vasculitis (AAV) - An Interim Analysis
Abstract Poster Presenter: Ravi Kumar U, DM – Christian Medical College
10:30 AM - 12:30 PM Central Time

Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review
Abstract Poster Presenter: Caitlyn Kanters, MD (she/her/hers) – McGill University
10:30 AM - 12:30 PM Central Time

Cyclophosphamide versus Rituximab in the treatment of Anca-associated Vasculitis: Adverse events and Relapses
Abstract Poster Presenter: Fabricio Benavides, MD – Hospital Universitario Marqués de Valdecilla
10:30 AM - 12:30 PM Central Time

Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients
Abstract Poster Presenter: Benjamin Terrier, MD, PhD (he/him/his) – Cochin Hospital
10:30 AM - 12:30 PM Central Time

Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study
Abstract Poster Presenter: lucas khellaf, MD, MMSc (he/him/his) – Sorbonne University
10:30 AM - 12:30 PM Central Time

Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series
Abstract Poster Presenter: Helen Au, MBBS – Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim
10:30 AM - 12:30 PM Central Time

Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study
Abstract Poster Presenter: Yusuke Ushio, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
10:30 AM - 12:30 PM Central Time

SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
Abstract Poster Presenter: Julia Foos, BA – University of Toledo College of Medicine
10:30 AM - 12:30 PM Central Time

Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis
Abstract Poster Presenter: Brendan Denvir, MD (he/him/his) – Johns Hopkins School of Medicine
10:30 AM - 12:30 PM Central Time

Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
Abstract Poster Presenter: Peter Merkel, MD, MPH – University of Pennsylvania
10:30 AM - 12:30 PM Central Time

GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency
Abstract Poster Presenter: Brendan Denvir, MD (he/him/his) – Johns Hopkins School of Medicine
10:30 AM - 12:30 PM Central Time

Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Abstract Poster Presenter: Miriam Guerini, MBChB – IRCCS Policlinico San Matteo, University of Pavia
10:30 AM - 12:30 PM Central Time

Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
Abstract Poster Presenter: Benjamin Terrier, MD, PhD (he/him/his) – Cochin Hospital
10:30 AM - 12:30 PM Central Time

Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study
Abstract Poster Presenter: Fabricio Benavides, MD – Hospital Universitario Marqués de Valdecilla
10:30 AM - 12:30 PM Central Time

Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Abstract Poster Presenter: Adrien Cottu – Sorbonne Université